Tumor necrosis factor α increases antifibrinolytic activity of cultured human mesangial cells  by Meulders, Quentin et al.
Kidney International, Vol. 42 (1992), pp. 327—334
Tumor necrosis factor a increases antifibrinolytic activity of
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Tumor necrosis factor a increases antifibrinolytic activity of cultured
human mesangial cells. Tumor necrosis factora (TNFa) is likely to exert
a major influence in the pathogenesis of glomerulopathies. Besides its
proinflammatory properties, TNFa interacts with cell growth and
synthesis of components of the fibrinolytic system. In this study, we
report the effects of recombinant human TNFa on the synthesis of
tissue-type plasminogen activator (t-PA) and its inhibitor (PAT-i) by
human mesangial cells in culture. We first demonstrate that TNFa binds
specifically to a single class of high affinity receptors (Kd 5. l0
1500 receptors/cell). TNFa has an antimitogenic effect on human
mesangial cells since it decreased DNA synthesis, measured by 3H-
thymidine incorporation, in a dose-dependent manner. Release of
cytosolic LDH and incorporated 51Cr was not increased by 100 ng/ml
TNFa as compared with control, indicating that this monokine is not
cytotoxic for cultured human mesangial cells. Zymographic analysis
and reverse fibrin autography disclosed a 120 kD t-PA-PAL-1 complex
and a 50 kD free form of PAl-I in the supernatants of both unstimulated
and TNF-stimulated cells; PAT-I was released in excess and free t-PA
was not observed. TNFa (0 to 100 ng/ml) had no effect on t-PA
synthesis, but enhanced PAl-i release in a time- and dose-dependent
manner (97% increase of PAl-I synthesis after a 24 hour incubation).
This effect was abolished by cycloheximide, suggesting that protein
synthesis was required. Northern blot analysis showed that TNFa
increased the steady-state PAl-I mRNA levels in a time-dependent
manner, with a maximal effect at two hours. Finally, in contrast to what
was reported for rat mesangial cells, we failed to demonstrate a
production of TNFa in human mesangial cells themselves by immuno-
radiometric assay, immunocytochemistry and Northern blot analysis
using a specific TNFa cDNA probe. We conclude that TNFa has an
antimitogenic activity on human mesangial cells in culture and enhances
the synthesis of PAL-i. Whether TNFa plays a role in glomerular PAl-i
deposition and persistency of librin in vivo remains to be determined.
Tumor necrosis factor-alpha (TNFa), a monocyte/macro-
phage-derived polypeptide of 17 kD, plays a prominent role in
many cell functions, including prostaglandins, collagenase and
interleukin-1 synthesis, induction of surface antigens on endo-
thelial cells, expression of interleukin-2 receptors on T-cells [1,
21 and mitogenic activity on several cell types including rat
mesangial cells [31. In addition to its potent proinflammatory
activities, TNFa modulates hemostasis, a property shared with
interleukin- 1. It stimulates procoagulant activity [4, 51 and also
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increases antifibrinolytic activity [6, 7]. Fibrinolysis is a highly
regulated process which involves several components: Uroki-
nase (u-PA) and tissue-type plasminogen activator (t-PA) are
specific proteases that convert the blood plasma zymogen
plasminogen into the trypsin-like protease plasmin. Fibrin, the
solid support of the blood clot, is one of the substrates for
plasmin [8]. Two specific plasminogen activator inhibitors,
PAl-i and PAI-2, were purified from bovine endothelial cells [9]
and human placenta [101, respectively. Glomerular cells have
previously been shown to produce components of the fibrino-
lytic system [11]. Glomerular epithelial cells synthesize u-PA
and PAl-i [12], whereas cultured human mesangial cells pro-
duce t-PA and PAl-i [13]. The renal fibrinolytic system is
required for the removal of intravascular clots, and could also
be involved in the extravascular proteolysis, for the rehandling
of basement membrane and extracellular matrix [14]. Fibrin
deposition is frequently observed in experimental and human
nephropathies, particularly in extracapillary glomerulonephritis
and vasculitis [15]. Deposits of fibrin may injure glomeruli
through several ways: Occlusion of glomerular capillaries,
attraction of inflammatory cells and direct cytotoxicity to
mesangial cells [16]. More recently, PAl-i was shown to be
associated to fibrin deposits in severe forms of human glomer-
ulonephritis and vascular nephropathies [17], which suggests
that persistency of fibrin is related to a local inhibition of
fibrinolytic activity. As TNFa was demonstrated to increase
PAl-i synthesis [6] and to be produced in some experimental
nephropathies [18], the question arises whether TNFa could
increase the local synthesis of PAl-i by glomerular cells.
In this study, we demonstrate the presence of TNFa recep-
tors on human mesangial cells and show that TNFa increases
the synthesis of PAl-i by these cells. We also show that, in
contrast with rat mesangial cells [3, 19], human mesangial cells
do not produce TNFa and do not proliferate in response to this
cytokine, at least in these conditions of culture.
Methods
Material
The following materials were used: Collagenase type IV,
bacterial lipopolysaccharide, cycloheximide, from Sigma
Chemical Co. (St. Louis, Missouri, USA); purified human
alpha-thrombin (3,000 U/mg) from Doctor Freyssinet, Stras-
bourg, France; low melting point agarose from BRL (USA),
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polyvinyl chloride U microtiter plates from Dynatech Labora-
tories (Alexandria, Virginia, USA); purified fibrinogen and
plasminogen from AB Kabi (Stockholm, Sweden); human
urokinase reference standard grade (100,000 U/mg) from Choay
(Paris, France); human t-PA (600,000 U/mg), goat polyclonal
antihuman t-PA IgG, goat polyclonal antihuman PAl-i IgG and
mouse monoclonal antihuman PAl-i antibody (MA! 12) from
Biopool (Sweden). Highly purified recombinant human TNF-a,
purified rabbit anti-human TNFa IgG from Professor Schleun-
ing (Berlin, Germany); purified '251-labeled human TNFa, 505
Ci/mmol, recombinant human interleukin-l and interleukin-2,
tritiated thymidine, alpha 32P dCTP> 3000 Ci/mmol from the
Radiochemical Center (Amersham, UK). Controlled purified
rTNFa was cytotoxic for L929 cells. Titration indicated 3.106
U/lOO jsg rTNFa. This effect was inhibited by rabbit polyclonal
anti-TNFa IgG from Genzyme (not shown).
Mesangial cells in culture
Glomeruli were isolated from normal human kidneys judged
to be unsuitable for transplantation, as previously described
[13]. In brief, thin (2 to 4 mm) strips of decapsulated kidney
cortex were minced in culture medium. Small fragments of
tissue were pushed through 90-mesh stainless steel screens with
a glass pestle. The resulting mixture containing glomeruli was
then passed over a graded series of screens, and single, unen-
capsulated glomeruli were finally retained on a fine mesh
screen, washed and sedimented in basal medium. These steps
resulted in a preparation of glomeruli virtually free of non-
glomerular contaminants.
For isolation of contractile mesangial cells, isolated glomeruli
were digested by 750 U/mi collagenase type IV for 30 minutes
as described [13]. The glomerular suspension was sieved over a
stainless mesh screen and isolated epitheiiai cells were recov-
ered in the filtrate after repeated washings. The remaining
glomerular fragments were recovered and expianted in 10 cm
Petri's dishes in complete Waymouth's medium supplemented
with 20% fetal calf serum (FCS). The glomeruli were incubated
at 37°C in a humidified 5% CO2 incubator. By this method
smooth muscle-like mesangial cells appeared from the glomeruli
approximately 8 to 14 days following attachment. They have
been previously characterized by morphological and biochem-
ical properties [13, 201. They appeared large and stellate.
Immunofluorescence studies with specific polyclonal antibody
raised against von Willebrand factor were negative. To further
eliminate any contamination by either epithelial or endothelial
cells, all experiments were performed between the third and
fifth passages.
Experiments in cell cultures
Mesangial cells were plated in multidish wells and grown in
RPM! medium supplemented with 10% FCS, 100 lU/mi peni-
cillin and 50 .tg/ml streptomycin. Twenty-four hours before the
experiments, medium was removed and replaced with a serum-
free minimum defined medium (48.7% HAM F12, 48.7%
DMEM, 1% HEPES, 1% glutamin, 0.05% penicillin) to prevent
contamination of conditioned medium by t-PA or PA!-! from
FCS. The day of the experiment, the subconfluent cells were
incubated for 24 or 48 hours with the substances to be tested or
vehicles alone. At the end of this period, supernatants were
collected, adjusted to 0.1% Tween and then stored at —20°C.
Adherent mesangial cells were detached by trypsin-EDTA and
counted in a Malassez plate. Trypan blue dye was used in all
experiments to determine cell viability. Cytotoxicity was eval-
uated in some experiments by measurement of lactic dehydro-
genase in the supernatants and release of 51Cr, as described
[21].
Characterization of human TNFa receptors
Purified '251-labeled human TNFa (Amersham, UK) with a
specific activity of 505 Cilmmol was used for binding experi-
ments. Adherent mesangial cells cultured in the presence of
10% FCS were washed three times with Waymouth's medium
containing 1 mg/mi bovine serum albumin (BSA) and then
incubated at 4 or 22°C with '25!-TNFa in Waymouth's medium
containing 0.1 mg/mi BSA (5. lO CPM/plate corresponding to
1.5 10— 13 M labeled ligand). At the end of incubation the
supernatant was removed, cells were washed three times with
Waymouth's medium containing 1 mg/mi BSA, then dissolved
in 1 M NaOH, and radioactivity was counted in a gamma-ray
counter. Each experiment was carried out in duplicate. Specific
binding was obtained by subtracting the counts bound in the
presence of l0 M unlabeled recombinant human TNFa. To
unmask TNFa receptors, which could have bound endogenous
or exogenous contaminant TNFc, the cells were treated for
three minutes at 4°C with 50 mi glycine-HCI buffer, pH 3,
containing 0.1 M NaCl, then quickly neutralized with 50 mri
HEPES buffer (pH 7.5), 0.1 M NaCl, and washed. Acidic
treatment has been shown to dissociate polypeptide ligands
from their receptors [22]. For binding assays, protein concen-
tration was measured as described by Lowry [23].
Competitive inhibition of labeled TNFa binding by unlabeled
TNFa at various concentrations was performed by adding
simultaneously both labeled and unlabeled ligands. Bindings
were measured after three hours at 4°C.
Immunoradiometric assay of TNFa
To determine if human mesangial cells produce TNFa as rat
mesangial cells [19], cells were stimulated 24 hours at 37°C by
10 sg/ml bacterial lipopolysaccharide (LPS, Sigma) and 50 U/mi
recombinant human interleukin-2 (IL-2, Amersham). Standards
and samples were tested in tubes precoated with an anti-human
TNFa monoclonal antibody, and a '25!-antibody was added at
the same time (IRMA, Medgenix, Belgium). After overnight
incubation, the tubes were washed three times and counted in a
gamma-counter. The assay does not cross react with TNF-f3
and its sensitivity is 15 pg/mI. The interassay and intraassay
variations were respectively 7 and 6% for a TNFa concentra-
tion of 65 pg/mi.
Immuno gold-silver staining technique (IGSS) with bright-field
and epipolarization microscopy
To look for the presence of a transmembrane form of TNFa,
cells were plated on glass coverslips and incubated for three
hours at 37°C with 10 g/ml LPS. After fixation in 2% glutaral-
dehyde, 0.1 M sodium phosphate buffer (PBS), 1% paraformal-
dehyde for 10 minutes, glass slides were washed in PBS and
incubated with purified rabbit anti-human TNFa !gG (from Pr.
Schleuning, Berlin, Germany) for 30 minutes at room temper-
ature. The slides were washed in PBS and incubated with
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biotinylated anti-rabbit IgG, rinsed in PBS and treated with
gold-labeled streptavidin (5 nm gold) for 60 minutes. The slides
were washed in distilled water before amplification with silver
enhancement reagent (Soussen) for 10 minutes, and counter-
stained with GIEMSA solution [241. Slides were observed with
combined bright-field and epipolarization microscopy (Leitz-
Orthoplan).
Thymidine incorporation assay
Subconfluent cultured cells were incubated 18 hours in min-
imum defined medium (MDM) supplemented with TNFa at
various concentrations. Then, 3H-thymidine (Amersham, UK)
was added in each well (1 pCi/mI) for six hours. After incuba-
tion, cells were rinsed three times with RPM! containing 10%
FCS and 1 mg/mi cold thymidine was added for 30 minutes.
Cells were detached by trypsin-EDTA, counted, and radioac-
tivity was measured in a a-counter (LKB Rackbeta, Switzer-
land). As positive control for cell growth, experiments were
also performed with 1 U/ml a-thrombin as previously reported
[25].
Zymography and reverse fibrin autography
After separation by 10% SDS polyacrylamide gel electropho-
resis (SDS-PAGE), plasminogen activator activity was detected
on a fibrin agar underlay (fibrinogen 10 mg/mI, thrombin 300
mU/mi, agarose 1%, plasminogen 20 jg/ml) containing plasmin-
ogen as previously described [13, 26]. Incubation was per-
formed at 37°C under humidified atmosphere.
To detect plasminogen activator inhibitors by reverse fibrin
autography [91, u-PA (0.1 U/mi final concentration) was added
to the fibrin agar underlay. Progressive lysis of the fibrin film
was observed after incubation at 37°C, except at the location of
plasminogen activator inhibitor.
Enzyme-linked immunosorbent assay (ELISA) of t-PA and
PAl-i
ELISA oft-PA and PAl-i were made as previously described
[13, 26]. ELISA of PA!-! was slightly modified: Microtiter
poiyvinylchloride plates were coated with 5 g/ml specific goat
poiyclonal antihuman PA!-! IgG (Biopool, Sweden). After
washing, samples to be tested were added for two hours at
37°C, and washed again. Free and complexed PAl-i were
detected with a mouse monoclonal anti-PAl- 1 antibody (250
nglml) which recognize both free PAl- 1 and complexed PAl- 1
(MA! 12, Biopool). Plates were then washed with PBS Tween
0.1% and incubated with diluted horseradish peroxidase cou-
pled with antimouse IgG (1/3000) for one hour at 37°C. There-
after, plates were washed and the reaction revealed by addition
of 1 mg/mI 0-phenylene diamine and hydrogen peroxide as
previously described [131. For the EL!SA of t-PA, plates were
coated with 5 pg/mi goat polyclonal antihuman t-PA !gG and
incubated with the samples to be tested. Free and complexed
t-PA bound to the plates were then revealed by biotinylated
anti-t-PA antibodies as previously reported [13]. The lowest
concentrations that could be detected were 0.4 ng/ml for PAI-l
and 0.14 ng/ml for t-PA. The interassay variations were 16%





Fig. 1. Time course of '25!-TNF-a binding (505 Ci/mmol) to human
mesangial cells cultured with 10% FCS. 50,000 cpm was added to each
well at 4°C (0) or 22°C (•). Results are expressed as cpm per mg
of cellular protein and represent specific binding. Specific binding is
determined by the total amount bound minus that bound in the presence
of lO M unlabeled r TNF-a (1000-fold excess). Each experiment was
performed in duplicate.
RNA extraction and Northern blot analysis
After incubation of glomerular mesangial cells in the various
conditions, total RNA was extracted by the phenol-chloroform
method as described [12], and precipitated by Li Cl (3 M). Total
RNA (10 pg/track) was separated by electrophoresis in 0.9%
agarose gel containing 20% formaldehyde and transferred to a
nylon membrane (Gene Screen Plus). Hybridization was per-
formed using a 32P-labeled cDNA probe specific for human
t-PA, PA!-1, TNFa or mouse J3-actin [13, 28]. After washing,
the same filter was rehybridized with another probe. Autorad-
iograms were developed after 24 to 72 hours. Messenger RNA
levels were quantitated by image processing and videodensito-
metry of autoradiograms (Appligene, Strasbourg, France).
The probes used were the l,000-bp Pstl insert of human
PAI-l cDNA (provided by Dr. David Loskutoff, Scripps Clinic
and Research Foundation, La Jolla, California, USA), the Bgl
II fragment of the pPA ii 4B cDNA harboring i948-bp of the
human t-PA cDNA as described [29], the insert of human
mature TNFa of plasmid BBG 18 (provided by Pr. Schleuning,
Berlin, Germany) and the 1000-bp Pstl fragment of f3-actin
cDNA (provided by Stephania Petrucco, !SREC, Epalinges,
Switzerland) as previously described [30].
Statistical analysis
Data are reported as means SEM. Results were compared
with Student's t-test or two-way variance analysis (ANOVA),
when appropriate.
Results
Characterization of TNFa receptors on human mesangial
cells
Specific TNFa receptors could be demonstrated at the sur-
face of mesangial cells. Figure 1 shows the time course of
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Fig. 2. Competitive inhibition of'251-TNF-a binding on human mesan-
gial cells. Experiments were performed at 4°C for 3 hours by adding
ligand (50,000 cpm) in the absence or presence of IO to iO M
unlabeled TNF (•), 3.1O M gamma-IFN (A), 3.l0- M IL-2 (0),
3.10—10 M IL-1/3 (0) and 6. l0 M GM-CSF (s). Results are expressed
as cpm io per well (specific binding) and Scatchard plot analysis
(inset). Each experiment was performed in duplicate.
observed at the highest temperature, and a plateau was reached
after three and four hours at 22 and 4°C, respectively. The
maximal specific binding was twofold higher at 22°C than at
4°C. Non-specific binding ranged from 10 to 30% of total
binding. The binding of TNFa was not modified when cells
were pretreated by acid buffer, a treatment which dissociates
polypeptide ligands from their receptors [22].
The binding of TNFa was partially reversible when unlabeled
TNFa (l0— M) was added two hours after labeled TNFa at
22°C (not shown). Specificity of the binding was demonstrated
by competitive inhibition: Unlabeled TNFs displaced labeled
TNFa, whereas IL-1/3, IL-2, y-IFN and GM-CSF at similar
concentrations did not (Fig. 2). Competitive inhibition of TNFa
binding at 4°C and Scatchard plot analysis showed a single class
of high affinity receptors with an apparent dissociation constant
(Kd) of 5. l011 M (mean of 2 separate experiments) and a
receptor site concentration of 1500 per cell (Fig. 2).
Absence of TNFa synthesis by human mesangial cells
To further investigate if human mesangial cells do not pro-
duce TNFa, supernatants of 10 g/ml LPS or 50 U/mI IL-2-
stimulated human mesangial cells were studied. TNFa could
not be detected by a sensitive immunoradiometric assay
(IRMA) after 24 hours of incubation at 37°C (<15 pglml).
Moreover, an attempt of immunolocalization of transmembrane
TNFa in LPS-stimulated cells by another sensitive method
(immunogold-silver staining) was unsuccessful. Finally, there
was no TNFa messenger RNA in unstirnulated human mesan-
gial cells. Incubation with 10 tg/ml LPS for two hours (not
shown) or 0.1 g/ml cycloheximide to inhibit mRNA degrada-
tion was unsuccessful; LPS-stimulated peripheral blood mono-
nuclear cells were used as positive control (Fig. 3).
Thymidine incorporation
As TNFa has growth factor activity in rat mesangial cells
cultured in serum-free medium [3], thymidine incorporation by
Fig. 3. Northern blot analysis of human mesangial cells with a
labeled human TNF-a cDNA probe. Ten g of total RNA from human
mesangial cells and peripheral blood mononuclear cells (PBMC) were
harvested after a 4 hour incubation. (1): unstimulated mesangial cells;
(2): mesangial cells cultured with 0.1 g/ml cycloheximide; (3) unstim-
ulated PBMC; (4): 10 tg/ml LPS-activated PBMC.
Fig. 4. Dose-response effect of rTNF-a on DNA synthesis in human
mesangial cells cultured 24 hours in the absence of FCS. Incorporation
of 3H-thymidine (I sCi per well) in the presence of rTNF-a or I U/mI
a-thrombin with or without 100 ng/ml rTNF-a was expressed as percent
of control. Mean SEM of 4 experiments made in duplicate are given.
THR: a-thrombin; *p < 0.05 as compared with control conditions; and
**p < 0.01 as compared with a-thrombin addition alone.
human mesangial cells treated with TNFa was measured.
TNFa decreased thymidine incorporation in a dose-dependent
fashion (Fig. 4). This effect was significant with a concentration
of 10 ng/ml (P < 0.05) and thymidine incorporation was
diminished to 60% of control at 100 ng/ml (P < 0.01). Moreover,
TNFa completely abolished the known stimulating effect of 1
U/mi a-thrombin which was used as a positive control (P <
0.01). The number of viable cells was slightly but nonsignifi-
cantly decreased after 24 hours incubation with 10 or 100 ng/ml
TNFa. At these concentrations, TNFs had no cytotoxic effect
since lactic dehydrogenase (LDH) and 51Cr releases were not
enhanced in same experiments: LDH was 25.2 2 lU/mi in
control cells and 20.5 6 lU/mI with TNFa (NS); 51Cr release
was 18.6 0.9% of total 1Cr incorporated in control cells and
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Fig. 5. Effect of rTNF-a on i-PA and PAl-i activities by zymography
(A) and reverse fibrin autography (B). A. Zymography. Lane 1: control
human urokinase; lane 2: culture medium of unstimulated mesangial
cells; lane 3: culture medium of mesangial cells stimulated by 100 ng/ml
rTNF-a for 24 hours. B. Reverse fibrin autography. Lane I: control
human 50 kD PAT-I; lanes 2 and 3: same culture media as for
zymography.
Effect of TNFa on t-PA and PAl-i synthesis
By zymography (Fig. 5A), a 120 Kd form of plasminogen
activator was found in the supernatants of unstimulated and
TNFa-stimulated cells. This form has been previously charac-
terized and corresponds to t-PA-PAI-l complexes [131. There
was no free t-PA, nor urokinase as previously reported [13].
Free PAT-i, which was released in excess as compared with
t-PA, was detected in the supernatants by reverse fibrin autog-
raphy (Fig. 5B). Since zymography is not a quantitative
method, we measured the effects of TNFa on t-PA and PAT-i
antigen levels determined by ELISA.
TNFa did not exert influence on t-PA synthesis (Fig. 6) but
stimulated PAl-i release in a dose- and time-dependent manner
(Figs. 6 and 7). PAl-I synthesis increased significantly when
cells were incubated 24 hours with 0.1 ng/ml TNFa (P < 0.005)
and was twofold higher with 100 ng/ml TNFs as compared with
unstimulated conditions. Maximal and significant PAI-l release
occurred after 24 hours of incubation. Two-way analysis of
variance indicated that both time and TNFa effects were
significant on PAl-I release (P < 0.025 and P < 0.005, respec-
tively) without significant statistical interaction.
Q)
Mechanisms of increased synthesis of PAl-i
The effect of TNFa on PAl-I release was tested in the
presence of cycloheximide, an inhibitor of protein synthesis in
a 24-hour incubation. Cycloheximide (0.1 gImI) completely
abolished the 100 ng/mI TNFa-induced PAl-i production,
whereas cycloheximide alone had no effect [unstimulated cells,
3.46 0.14 ng/102 cells; cycloheximide alone, 3.75 0.11
ng/102 cells (NS); 100 ng/ml TNFa alone, 6.66 1.07 ng/102
cells (P < 0.05); TNFa + cycloheximide, 4.18 0.75 ngIiO2
cells (P < 0.025 vs. TNFa alone)]. By Northern blot analysis,
TNFa was shown to increase the levels of PAl-I mRNA but not
the levels of t-PA mRNA in a time-dependent fashion (Fig. 8).
PAI-l mRNA level in TNF-stimulated mesangial cells was
maximal after a two-hour incubation and was still increased at














Fig. 6. Dose-response effect of rTNF-a on t-PA (black columns) and
PAl-i (hatched columns) antigen release by human inesangial cells in
a 24 hour incubation. Results are expressed as ng/number of cells.
Mean SEM of 4 experiments made in duplicate are represented. <
0.005 as compared with control conditions.
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Fig. 7. Time-course of PAZ-i antigen release by human mesangial cells
in the absence (E) or presence (•) of 100 ng/ml rTNF-a. Results are
expressed as ng/number of cells. Mean SCM of 4 experiments made in
duplicate are given. **p < 0.005 as compared with control conditions.
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Fig. 9. Quantification of mRNA levels by videodensitometry. Results
are expressed as PAI-l//3-actin mRNA ratio of unstimulated cells (solid
white bars) or TNF-a-stimulated cells (solid black bars). t-PAI/3-actin
mRNA ratio of unstimulated cells (hatched light bars) or TNF-a-
stimulated cells (hatched dark bars).
Discussion
Our study demonstrates that TNFa increases the synthesis of
PAl-i by human mesangial cells in culture, and that this effect
is mediated through specific binding to one class of high affinity
receptors and presumably PAl- 1 gene transcription and de novo
PAl-i synthesis.
Similar high affinity receptors for TNFa have been identified
on a variety of transformed and normal cell lines, with apparent
Kd ranging from 4.4 l0 to 3.4 i0 M, and number of
receptor sites/cell between 200 and 50,000 [21, 31, 32]. It was
reported that after binding of TNFa to its receptor [33],
agonist-receptor complexes are internalized [33] and further
recycled in some cell types [341. The incomplete reversibility of
'251-TNFa binding by addition of unlabeled ligand in large
excess at 22°C could preferentially credit the possibility of
ligand-receptor complex internalization in mesangial cells. Re-
ceptor mobility is lower at 4°C, and the plateau of TNFs
binding was significantly decreased when compared with the
— 3.4kb
— 2.2 kb
Fig. 8. Northern blot analysis of human
— 2.5 kb mesangial cells: Time-course effect of TNF-a
on t-PA and PAl-I mRNA. Ten &g of total
RNA from human mesangial cells incubated
for 2 (lanes 1 and 2), 4 (lanes 3 and 4), 8
(lanes 5 and 6) and 24 (lanes 7 and 8) hours,
in control conditions (lanes 1, 3, 5, 7), or in
the presence of 100 ng/ml rTNF-a (lanes 2, 4,
6, 8) were used. t-PA mRNA (2.5 Kb), PAl-I
mRNA (3.4 and 2.2 Kb) and p-actin mRNA
(2.4 Kb) were revealed by the respective
specific probes.
22°C control; increased internalization and/or recycling of
TNFa receptors or increased expression of TNFa receptors on
cell membrane probably occur in mesangial cells at room
temperature. Further experiments, however, must be carried
out to clarify these phenomena.
Since TNFa was shown to be produced by rat mesangial cells
and act through an autocrine loop [19], we pretreated cultured
human mesangial cells by acid buffer to dissociate endogenous
TNFa, if any, from the receptors. No difference of binding was
found between acid-treated cells and controls, which suggests
that in unstimulated conditions, human mesangial cells in
culture do not produce TNFa. As TNFa release by rat mesan-
gial cells was detectable only after triggering by LPS [19], we
tried to measure TNFa concentrations in supernatants of hu-
man mesangial cells incubated with 10 g/ml LPS or 50 U/mI
rIL-2, the latter being known to stimulate TNFa release by
mononuclear cells [35]. TNFa measured in the supernatants by
a sensitive immunoradiometric assay was undetectable in these
conditions. Furthermore, immunohistochemical methods (im-
munogold-silver staining technique) designed to disclose the
transmembrane form of TNFa failed to demonstrate the cyto-
kine in LPS-activated human mesangial cells. This method was
previously shown in our laboratory to reveal membrane-asso-
ciated TNFa in LPS-activated rat mesangial cells [36]. Finally,
we could not find TNFa mRNA in LPS- and cycloheximide-
treated human mesangial cells. Therefore, we conclude that, at
least in these conditions, cultured human mesangial cells do not
synthesize detectable amounts of TNFa. Synthesis of this
cytokine by cultured mesangial cells could thus be species-
specific.
A mitogenic activity of TNFa was demonstrated for several
cell types but is highly dependent on experimental conditions,
for example: TNFa stimulates the growth of human fibroblasts
[1] but has no effect on osteoblast-like cells [37]; it reduces the
proliferation rate of endothelial cells in vitro but is angiogenic in
vivo [38]; growth of rat mesangial cells cultured in serum-free
medium (G0/G I phase) is enhanced by TNFa but not when cells
are cultured in the presence of serum [3]. The inhibitory effect
of TNFa on the proliferation of resting or thrombin-stimulated
human mesangial cells suggests that the activity of TNFa on
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mesangial cell growth is also species-specific. As shown by the
normal low release of LDH and previously incorporated cyto-
solic 51Cr, this inhibition was not due to a cytotoxic effect;
cytotoxicity is an important property of TNFa but seems to be
restricted to tumor cells [1, 39]. In a recent study, alterations of
cytoskeletal organization were observed in human mesangial
cells treated by TNFa. These alterations were demonstrated to
be reversible and not associated with cytotoxicity [40].
Our results show that TNFa increases the synthesis of PAL-i
by human mesangial cells but does not modify that of t-PA. We
have previously shown that human mesangial cells in culture
synthesize PAT-i in excess as compared to t-PA [13]. The time
course study of PA!-! production shows that a long incubation
period is required for this effect of TNFs, which suggests that
de novo transcription and protein synthesis are involved in the
process. This is confirmed by the effect of cycloheximide which
completely abolishes TNF-induced PAl-i release; Northern
blot analysis shows that it is mediated through an early increase
of PAL-i mRNA levels, whereas levels of mRNA coding for
t-PA are not altered in mesangial cells treated by TNFa. Our
results are in accordance with previous studies which demon-
strate that TNFa increases the PAl- 1 gene template activity in
fibrosarcoma cells [61. However, in contrast to HT-1080 cells,
TNFa does not seem to decrease the t-PA mRNA level in
human mesangial cells; this may be related to the very low basal
level of t-PA mRNA in these cells. Whether TNFa stimulates
PAl-i through an increase in prostaglandins or other autacoid
generation by mesangial cells cannot be excluded, although
human mesangial cells in culture were shown to produce very
low amounts of prostaglandins compared to rat mesangial cells
[41].
Recent studies suggest that TNFa plays a major role in the
behavior of mesangial cells [3, 40] and may play a pivotal action
in the pathogenesis of glomerulonephritis [18]. In a model of
nephrotoxic serum nephritis, high amounts of TNFa were
found to be released by isolated glomeruli (up to 20 ng/ml);
these concentrations were similar to those used in our in vitro
study [42]. Extrapolation of results derived from isolated cells
in culture to in vivo events remains a debated issue, but it is
likely that, in the course of several glomerular diseases charac-
terized by infiltration of mononuclear cells, TNFa exerts a
regulation on fibrinolytic activity by enhancing the synthesis of
PA!-! in human mesangial cells. TNFa is not directly cytotoxic
for mesangial cells. However, the role of fibrin deposits in
cellular toxicity and amplification of inflammatory process was
demonstrated [16]. As PAT-i is involved in persistency of fibrin
deposits and blood clots in capillaries [14, 15], it is likely that in
vivo TNFa contributes indirectly in injury of glomerular cells.
In conclusion, our results suggest that TNFa acts on human
mesangial cells through binding to a single class of high affinity
receptors. Two major differences with rat mesangial cell behav-
ior appeared: First, the antimitogenic effect of TNFs when
human cells were cultured in serum-free medium; and second,
the absence of TNFr synthesis by human mesangial cells
themselves. This cytokine does not exert direct cytotoxicity on
human mesangial cells in vitro but enhances their antifibrino-
lytic activity by increasing both synthesis and release of free
PAl-i. TNFa may thus play a role in the persistence of
glomerular fibrin deposits.
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